Efficacy and safety of absorbable hemostatic gauze combined with topical tranexamic acid in reducing perioperative blood loss in THA: a prospective, randomized, controlled, single-center study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074497

Enrollment

Unknown

Registered

2023-08-08

Start date

2023-08-20

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage hip disease

Interventions

Absorbable hemostatic gauze group:Absorbable hemostatic gauze was placed locally on the hip joint

Tranexamic acid group:Tranexamic acid was injected locally into the hip joint

Absorbable hemostatic gauze combined with tranexamic acid group:Hemostatic gauze was placed locally in the hip joint and tranexamic acid was injected

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: ? Age =18 years old, primary hip arthritis, osteonecrosis of the femoral head, osteoarthritis secondary to developmental dysplasia of the hip (Crowe type I, II), rheumatoid arthritis with hip involvement and other end-stage diseases failed to conservative treatment, and received total hip arthroplasty in our hospital; ? Cardiopulmonary function was normal, and there were no contraindications to surgery. ? Platelet and coagulation function were normal before operation. ? There was no obvious abnormality in the preoperative color Doppler ultrasound of both lower limbs.

Exclusion criteria

Exclusion criteria: ? Bilateral surgery, revision surgery, Crowe III, IV developmental dysplasia of the hip; ? Anemia patients: female hemoglobin IV grade; ? patients receiving warfarin, heparin, estrogen therapy before surgery, history of hypercoagulation, deep vein thrombosis, history of pulmonary embolism, liver and kidney dysfunction, blood system diseases, severe heart and lung diseases.

Design outcomes

Primary

Measure	Time frame
Intraoperative dominant blood loss;Number of blood transfusions;The incidence of lower extremity venous thrombosis and pulmonary embolism;Total perioperative blood loss blood loss;Total perioperative blood loss blood loss;Types of blood transfusions;Blood transfusion volume;Incidence of pulmonary embolism;white blood cell count, percentage of neutrophils, erythrocyte sedimentation rate, C-reactive protein and interleukin-6 were recorded;	—

Measure

Time frame

Intraoperative dominant blood loss;Number of blood transfusions;The incidence of lower extremity venous thrombosis and pulmonary embolism;Total perioperative blood loss blood loss;Total perioperative blood loss blood loss;Types of blood transfusions;Blood transfusion volume;Incidence of pulmonary embolism;white blood cell count, percentage of neutrophils, erythrocyte sedimentation rate, C-reactive protein and interleukin-6 were recorded;

—

Secondary

Measure	Time frame
Length of hospital stay;range of motion of hip joint;Hip joint score;visual analogue scale pain score;patient satisfaction;	—

Countries

China

Contacts

Public ContactYi Zeng

West China Hospital, Sichuan University

zengyigd@126.com+86 189 8060 2289

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026